MYGN Q3 2025 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q3 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$206M-3.6% YoY

Gross Profit

$144M69.9% margin

Operating Income

-$23M-11.3% margin

Net Income

-$27M-13.3% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-3.5%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$18M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$728M

Total Liabilities

$355M

Stockholders' Equity

$373M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$206M	$213M	-3.6%
Gross Profit	$144M	$150M	-4.0%
Operating Income	-$23M	-$20M	-16.5%
Net Income	-$27M	-$22M	-24.0%

Geographic Segments

UNITED STATES

$192M93%

Non-US

$14M7%